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Thirty years ago, and a quarter of a
century after randomised trials had be-
come widely accepted, Archie Cochrane
reproached the medical profession for not
having managed to organise a ‘‘critical
summary, by speciality or subspeciality,
adapted periodically, of all relevant ran-
domised controlled trials’’ [1]. Thirty
years after Cochrane’s reproach we feel
it is timely to consider the extent to which
health professionals, the public and policy-
makers could now use ‘‘critical summa-
ries’’ of trials for their decision-making.
The Landscape
Keeping up with information in health
care has never been easy. Even in 1753,
when James Lind published his landmark
review of what was then known about
scurvy, he needed to point out that ‘‘…
before the subject could be set in a clear
and proper light, it was necessary to
remove a great deal of rubbish’’ [2]. And
20 years later, Andrew Duncan launched a
publication summarising research for cli-
nicians, lamenting that critical information
‘‘…is scattered through a great number of
volumes, many of which are so expensive,
that they can be purchased for the libraries
of public societies only, or of very wealthy
individuals’’ [3]. We continue to live with
these two problems—an overload of
unfiltered information and lack of open
access to information relevant to the well-
being of patients.
A century later, the precursor of the US
National Library of Medicine (NLM)
began indexing the medical literature.
Between 1865 and 2006, the index grew
from 1,600 references to nearly 10 million
[4]. Even with the assistance of electronic
databases such as NLM’s MEDLINE, the
problem of having to trawl through and
sift vast amounts of data has grown. As
mountains of unsynthesised research evi-
dence accumulate, we need to keep
improving our methods for gathering,
filtering, and synthesising it. Some of the
key events in the story so far are shown on
the timeline in Figure 1.
A legal regulatory framework overseen
by the US Food and Drug Administration
(FDA) requiring proof of efficacy of new
drugs was introduced in 1962, and other
countries followed suit. These develop-
ments made it inevitable that randomised
trials would increasingly become an im-
portant component of the evidence base
[5]. Government health technology assess-
ment agencies were also established as
policymakers sought to have more reliable
evidence of the effects of other forms of
health care interventions [6].
As the number of clinical trials grew, so
too did the science of reviewing trials.
Systematic reviews and meta-analyses
endeavouring to make sense of multiple
trials began to appear in a variety of health
fields in the 1970s and 1980s (see Box 1).
An important early example showed that
postoperative radiotherapy after surgical
treatment of breast cancer was associated
with a previously unrecognised increased
risk of death [7]. Another challenged
beliefs about vitamin C and the common
cold [8]. A third suggested a previously
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Summary Points
N When Archie Cochrane reproached the medical profession for not having
critical summaries of all randomised controlled trials, about 14 reports of trials
were being published per day. There are now 75 trials, and 11 systematic
reviews of trials, per day and a plateau in growth has not yet been reached.
N Although trials, reviews, and health technology assessments have undoubtedly
had major impacts, the staple of medical literature synthesis remains the non-
systematic narrative review. Only a small minority of trial reports are being
analysed in up-to-date systematic reviews. Given the constraints, Archie
Cochrane’s vision will not be achieved without some serious changes in course.
N To meet the needs of patients, clinicians, and policymakers, unnecessary trials
need to be reduced, and systematic reviews need to be prioritised. Streamlining
and innovation in methods of systematic reviewing are necessary to enable
valid answers to be found for most patient questions. Finally, clinicians and
patients require open access to these important resources.
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unrecognised advantage of some forms of
fetal monitoring during labour in reducing
neonatal seizures [9].
By the mid-1980s, the need to minimise
the likelihood of being misled by the effects
of biases and the play of chance in reviews
of research evidence was being made
evident in articles [10–14] and textbooks
[15]. In 1988, regularly updated electronic
publication of systematic reviews and
meta-analyses, along with bibliographies
of randomised trials, began in the perina-
tal field [16,17]. This provided a model for
the inauguration of the international
Cochrane Collaboration in 1993 to pre-
pare, maintain, and disseminate systematic
reviews of the effects of health care
interventions.
Where Are We Now?
Despite this progress, the task keeps
increasing in size and complexity. We still
do not know exactly how many trials have
been done. For a variety of reasons, a large
proportion of trials have remained unpub-
lished [18,19]. Furthermore, many trials
have been published in journals without
being electronically indexed as trials,
which makes them difficult to find. One
of the first steps in being able to adequate-
ly review literature is that scientific
contributions which predate digitalised
information systems and trial indexing
need to be ‘‘rediscovered and inserted into
the memory system’’ [20]. Through the
1990s, to identify possible reports of
controlled trials, the Cochrane Collabora-
tion mobilised thousands of volunteers
around the globe to comb the major
databases, and to hand-search nondigita-
lised health literature, unpublished confer-
ence proceedings, and books. The result of
this collaborative effort is the Cochrane
Controlled Trials Register (CCTR) (now
called the Cochrane Central Register of
Controlled Trials).
The differences between the numbers of
trial records in MEDLINE and CCTR
(see Figure 2) have multiple causes. Both
CCTR and MEDLINE often contain
more than one record from a single study,
and there are lags in adding new records
to both databases. The NLM filters are
probably not as efficient at excluding non-
trials as are the methods used to compile
CCTR. Furthermore, MEDLINE has
more language restrictions than CCTR.
In brief, there is still no single repository
reliably showing the true number of
randomised trials. Similar difficulties apply
to trying to estimate the number of
systematic reviews and health technology
assessments (HTAs).
In Figures 2 and 3 we use a variety of
data sources to estimate the numbers of
trials and systematic reviews published from
1950 to the end of 2007 (see Text S1). The
number of trials continues to rise: although
the data from CCTR suggest some fluctu-
ation in trial numbers in recent years, this
may be misleading because the Cochrane
Collaboration virtually halted additions to
CCTR as it undertook a review and internal
restructuring that lasted a couple of years.
Figure 1. Policy and academic milestones in the development of trials and the science of reviewing trials.
doi:10.1371/journal.pmed.1000326.g001
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Box 1. Early Systematic Reviews of the Effects of Health Care Interventions
N Stjernswa¨rd J (1974) Decreased survival related to irradiation postoperatively in early breast cancer. Lancet 304: 1285-1286.
N Chalmers TC (1975) Effects of ascorbic acid on the common cold. An evaluation of the evidence. Am J Med 58: 532-536.
N Cochran WG, Diaconis P, Donner AP, Hoaglin DC, O’Connor NE, Peterson OL, Rosenoer VM (1977) Experiments in surgical
treatments of duodenal ulcer. In: Bunker JP, Barnes BA, Mosteller F, eds. Costs, risks and benefits of surgery. Oxford: Oxford
University Press. pp 176-197.
N Smith ML, Glass GV (1977) Meta-analysis of psychotherapy outcome studies. Am Psychol 32: 752-760.
N Hemminki E, Starfield B (1978) Routine administration of iron and vitamins during pregnancy: Review of controlled clinical
trials. Br J Obstet Gynaecol 85: 404-410.
N Hemminki E, Starfield B (1978) Prevention and treatment of premature labour by drugs: Review of controlled clinical trials. Br J
Obstet Gynaecol 85: 411-417.
N Chalmers I (1979) Randomized controlled trials of fetal monitoring, 1973–1977. In: Thalhammer O, Baumgarten K, Pollak A,
eds. Perinatal medicine. Stuttgart: Georg Thieme. pp 260-265.
N Policy Research Incorporated (1979) Medical Practice Information Demonstration Project. Bipolar disorder, a state of the
science report. Baltimore: Policy Research Incorporated.
N Editorial (1980) Aspirin after myocardial infarction. Lancet 1:1172-1173. [Published anonymously but written by Richard Peto.]
N Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Fagerstrom RM (1981) A survey of clinical trials of antibiotic prophylaxis
in colon surgery: Evidence against further use of no-treatment controls. N Engl J Med 305:795-799.
N Hampton JR (1982) Should every survivor of a heart attack be given a beta-blocker? Part I: Evidence from clinical trials. BMJ 285:33-36.
N Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH (1982) Effect of intravenous streptokinase on acute myocardial
infarction: Pooled results from randomized trials. N Engl J Med 307: 1180-1182.
N Sacks HS, Chalmers TC, Berk AA, Reitman D (1985) Should mild hypertension be treated? An attempted meta-analysis of the
clinical trials. Mt Sinai J Med 52: 265-270.
N Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: An overview of the
randomized trials. Prog Cardiovasc Dis 27: 335-371.
Figure 2. The number of published trials, 1950 to 2007. CCTR is the Cochrane Controlled Trials Registry; Haynes filter uses the ‘‘narrow’’
version of the Therapy filter in PubMed:ClinicalQueries; see Text S1.
doi:10.1371/journal.pmed.1000326.g002
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Even though these figures must be seen
as more illustrative than precise, multiple
data sources tell the same story: astonish-
ing growth has occurred in the number of
reports of clinical trials since the middle of
the 20th century, and in reports of
systematic reviews since the 1980s—and
a plateau in growth has not yet been
reached. With a median of perhaps 80
participants per trial, the number of
people being enrolled in trials is likely to
be more than 2,000,000 per year [21].
Prospective trial registration establishes a
new genre of evidence repository: trials are
registered in these databases at inception,
theoretically enabling an overview of all
published and unpublished trials.
In 2004, the International Committee
of Medical Journal Editors (ICMJE,
http://www.icmje.org/) announced that
their journals would no longer publish
trials that had not been prospectively
registered [22]. Before this announcement,
an average of 30 trials a week were being
prospectively registered around the world.
Once the journal editors’ deadline came
into force, more than 200 ongoing trials
per week were being registered [23]. In
2007, the US Congress made detailed
prospective trial registration legally man-
datory [24]. As WHO’s international
clinical trials platform develops, it will
become possible to generate a more
realistic picture of how many trials are
being done. This registry draws together
standardised core data from all the trial
registries meeting specified quality criteria.
Registering full protocols and reporting
trial results in these registries are the next
frontiers.
How Close Are We to Archie
Cochrane’s Goal?
In 1986 and 1987, Goldschmidt and
Mulrow showed how great the potential is
for error in reviews of health literature that
were not conducted systematically [9,10].
Looking at data such as those in Figure 3
could provide the comforting illusion that
systematic reviews have displaced other
less reliable forms of information. Howev-
er, as Figure 4 shows, this is far from the
case. The growth has been even more
remarkable in non-systematic (‘‘narra-
tive’’) reviews and case reports. Journal
publishing of non-systematic reviews, and
the emergence of many journals whose
sole product is non-systematic reviews, has
far outstripped the growth of systematic
reviews and HTAs, as impressive as the
latter has been. And the number of case
reports—which can also provide impor-
tant new information such as adverse
effects—is far higher than the number of
trials or systematic reviews. Trials, system-
atic reviews, and HTAs have undoubtedly
had major impacts, including on clinical
guidelines: they are more likely to be cited
and read than other study types [25].
However, the staple of medical literature
synthesis remains the non-systematic nar-
rative review.
Furthermore, we are a long way from
having all relevant trials incorporated into
good systematic reviews. The workload
involved in producing reviews is increas-
ing, and the bulk of systematic reviews are
now many years out of date [26]. The
median number of trials contained within
individual systematic reviews has been
Figure 3. The number of systematic reviews in health care, 1990 to 2007. INAHTA is International Network of Agencies for Health
Technology Assessment; the Montori systematic review filter is detailed in Text S1.
doi:10.1371/journal.pmed.1000326.g003
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variously estimated at between six and 16
(Cochrane reviews now include an average
of over 12 trials per review [27,28]; M
Clarke, personal communication), but
many reviews have covered much the
same territory. Thus, in the 30 years since
systematic reviews began in earnest, with
around 15 years of intensified and large-
scale reviewing effort, only a minority of
trials have been assessed in systematic
reviews. Given the triple constraint posed
by the growth in trials, the increasing
complexity of review methods, and current
resources, Archie Cochrane’s vision will
not be achieved without some serious
changes in course—in particular, with a
greater concentration on Cochrane’s use
of the word ‘‘relevant’’.
Where to Now?
First, we need to prioritise effectively
and reduce avoidable waste in the pro-
duction and reporting of research evidence
[29]. This has implications for trials as well
as systematic reviews. Some funders and
others will now not consider supporting a
trial unless a systematic review has shown
the trial to be necessary [30]. It is essential
that this requirement be more widely
adopted. And it is essential that reviews
address questions that are relevant to
patients, clinicians and policymakers.
Second, we may need to choose be-
tween elaborate reviews of a quarter of the
questions clinicians and patients have or
‘‘leaner’’ reviews of most of what we want
to know. The methodological standards
for systematic reviewing have been in-
creasing over time [28], and the evolution
of standards in the Cochrane Collabora-
tion and in HTA has been remarkable.
The increase in steps and reporting
required is reflected in the length of
reviews. Early Cochrane reviews could
typically be printed out in 10 or 20 pages,
even when they incorporated several trials.
Today, it is not unusual for a review by a
health technology agency to run to several
hundred pages. Often the reviews are
longer than the combined length of the
reports of all the included trials.
A contributing factor here is the in-
creasing expectation for reviews to include
study types other than randomised trials.
This will often be essential for detecting
less common adverse effects. However, the
inclusion of all study types to answer all
questions about the effects of treatments
would not necessarily provide better
quality information in every instance –
while it would unquestionably increase the
time and resource requirement for re-
views. While it is vital that reviews are
scientifically defensible, burdening those
preparing them with excessive require-
ments could result in having valid answers
to relatively few questions.
In particular, we need leaner and more
efficient methods of staying up-to-date
with the evidence. Using current methods,
the Cochrane Collaboration has not been
able to keep even half of its reviews up-to-
date [31], and other organisations are in a
similar predicament [32]. We need to
develop innovative methods to reduce the
labour of updating, and provide what
clinicians and patients need: an assurance
that a conclusion is not out of date, even if
not every later trial is included within
every analysis. It is also the responsibility
of reviewer authors and journal editors to
ensure that every new systematic review
places itself clearly in context of other
Figure 4. The rise in non-systematic reviews, case reports, trials, and systematic reviews, 1950 to 2007 (as identified in MEDLINE).
doi:10.1371/journal.pmed.1000326.g004
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systematic reviews and HTAs. It will be to
little avail to the average clinician, patient,
and information provider, however, if the
resulting knowledge is not comprehensible
and openly accessible.
Finally, although more funding for
evaluative clinical research internationally
remains a priority, more international
collaboration could result in better use
being made of resources for systematic
reviewing and HTAs. While multiple
reviews on topics can provide a rounded
picture of an area as well as a de facto
form of updating when the reviews are
conducted several years apart, there is also
considerable duplication of review effort.
In November 2009, an international
meeting in Cologne formed a new collab-
oration called ‘‘KEEP Up,’’ which will
aim to harmonise updating standards and
aggregate updating results. This should
reduce the workload and enable organisa-
tions to be alerted when there are
important shifts in evidence. Initiated
and coordinated by the German Institute
for Quality and Efficiency in Health Care
(IQWiG) and involving key systematic
reviewing and guidelines organisations
such as the Cochrane Collaboration,
Duodecim, the Scottish Intercollegiate
Guidelines Network (SIGN), and the
National Institute for Health and Clinical
Excellence (NICE), this effort will provide
a platform for tackling practical and
methodological issues involved in keeping
up-to-date.
There is nevertheless a risk that the
increasing burdens placed on the methods
of systematic reviewing could make the
goal of keeping up-to-date with the
knowledge won from trials recede ever
more quickly into the distance. Perhaps
one of the first questions we should ask
whenever an additional process or more
demanding methodology for systematic
reviewing is proposed is this: Will this
development serve or hinder our ability to
better understand and communicate
enough results from trials? In 1979, when
Archie Cochrane argued that we needed
critical summaries to keep up with the
crucial knowledge those trials were gener-
ating, there were perhaps 14 trials a day
being published. Thirty years later, it
would be just as hard to keep up with
the systematic reviews. Every day there are
now 11 systematic reviews and 75 trials,
and there are no signs of this slowing
down: but there are still only 24 hours in a
day.
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